Europe Diabetic Neuropathy Treatment Market

Europe Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-21796 Publication Date: April-2024 Number of Pages: 134
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The Europe Diabetic Neuropathy Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $454 million by 2031. The UK market is exhibiting a CAGR of 6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).

Europe Diabetic Neuropathy Treatment Market

As the condition's prevalence rises and the need for effective therapeutic interventions intensifies, the market for it is undergoing a rapid evolution. In recent years, there have been significant advancements in the understanding of this and the development of new treatment options.

Additionally, due to these developments, the management of this has shifted to place more importance on early detection and intervention to impede or halt the progression of nerve damage.

European research and innovation efforts contribute to developing novel and more effective treatment modalities for diabetic neuropathy. This includes discovering new pharmacological agents, biotechnological therapies, and medical devices specifically designed to target neuropathic symptoms. According to the European Commission, research and innovation on diabetes and related factors, such as obesity, has been a longstanding priority for the EU. Over EUR 1.25 billion has been devoted to support research in the last decade.

Free Valuable Insights: The Global Diabetic Neuropathy Treatment Market will Hit USD 7.4 Billion by 2031, at a CAGR of 7.3%

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Abbott Laboratories
  • Eli Lilly And Company
  • Pfizer, Inc.
  • Lupin Limited
  • Astellas Pharma, Inc.
  • Glenmark Pharmaceuticals Limited
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • McKesson Corporation
  • GlaxoSmithKline PLC (GSK)

Europe Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

By Drug Class

  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
  • Opioid
  • Capsaicin
  • Others

By Disorder Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo